Studies cited here
Body weight, event risk and symptoms: the quantities behind the percentages matter as much as the size of the figures.
Direct comparisons
SURPASS-2 supplies the opening comparison in adults with type 2 diabetes. SURMOUNT-5 supplies the tirzepatide-versus-semaglutide obesity weight-loss comparison examined on the direct-contest page. I’d read those shared-trial comparisons alongside results with other opponents or outcomes.
Placebo-controlled weight trials
STEP 1 supplies the weight-loss comparison at 68 weeks. STEP 5 adds the sustained result over 104 weeks. These are separate placebo-controlled trials.
Outcome trials
SELECT and FLOW anchor the cardiovascular and renal discussion. STEP-HFpEF examines heart-failure-related symptoms and physical limitations. The populations and outcomes deserve attention alongside each result.
Adverse findings
SUSTAIN-6 puts the cardiovascular benefit and diabetic-retinopathy complication result in the same trial. The semaglutide safety review broadens the discussion to gastrointestinal effects, biliary disease and less settled cancer signals.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity ↗
- Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial ↗
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes ↗
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ↗
- Safety of Semaglutide ↗
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity ↗
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes ↗